← Leaderboards
Bin Liu
University Of California San Francisco
$11,320,971
Attributed
$14,042,931
Total exposure
11
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,042,931 · 11
By mechanism
R01$12,992,151 · 8
R21$1,050,780 · 3
Top collaborators
- Jiang He6 shared
- Kole T Roybal3 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Susan J. Fisher$38,160,909
- Carolyn R Bertozzi$44,381,955
- Lenore Palma Pereira$9,175,126
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorNeoplastic CellSurface AntigensTissuesAntibodiesLibrariesCell SurfaceCellsAffinityBacteriophagesIn VitroAntigensBaseEpitopesMalignant Neoplasm Of ProstateIn VivoHuman Monoclonal AntibodiesTumor AntigensAntigen TargetingIn SituTechnologyXenograft ModelNeoplasm MetastasisBinding (Molecular Function)
Grant awards (36)
Targeting tumor-specific epitope for imaging and therapy for mesothelioma$696,447
R01 · FY2025 · CA
Combination antigen sensing engineered T cell for precise recognition and enhanced elimination of solid tumors$666,268
R01 · FY2025 · CA
Develop novel bispecific antibody-drug conjugates against metastatic lethal prostate cancer across subtype$561,495
R01 · FY2025 · CA · contact PI
Bispecific T cell engager targeting a highly specific tumor cell surface antigen$545,644
R01 · FY2025 · CA · contact PI
Combination antigen sensing engineered T cell for precise recognition and enhanced elimination of solid tumors$632,874
R01 · FY2024 · CA
Develop novel bispecific antibody-drug conjugates against metastatic lethal prostate cancer across subtype$553,090
R01 · FY2024 · CA · contact PI
Bispecific T cell engager targeting a highly specific tumor cell surface antigen$544,866
R01 · FY2024 · CA · contact PI
Combination antigen sensing engineered T cell for precise recognition and enhanced elimination of solid tumors$666,104
R01 · FY2023 · CA
Novel radioimmunoconjugates for targeted alpha-particle therapy of metastatic prostatic cancer$546,037
R01 · FY2022 · CA
Novel radioimmunoconjugates for targeted alpha-particle therapy of metastatic prostatic cancer$557,186
R01 · FY2021 · CA
Novel radioimmunoconjugates for targeted alpha-particle therapy of metastatic prostatic cancer$559,729
R01 · FY2020 · CA
Novel radioimmunoconjugates for targeted alpha-particle therapy of metastatic prostatic cancer$543,996
R01 · FY2019 · CA
Novel radioimmunoconjugates for targeted alpha-particle therapy of metastatic prostatic cancer$575,279
R01 · FY2018 · CA
Internalizing human antibody-targeted nanosized siRNA therapeutics$328,888
R01 · FY2016 · CA · contact PI
Internalizing human antibody-targeted nanosized siRNA therapeutics$328,888
R01 · FY2015 · CA · contact PI
Internalizing human antibody-targeted nanosized siRNA therapeutics$318,099
R01 · FY2014 · CA · contact PI
Identifying antigens bound by novel scFvs targeting all subtypes of mesothelioma$307,352
R01 · FY2013 · CA · contact PI
Internalizing human antibody-targeted nanosized siRNA therapeutics$306,391
R01 · FY2013 · CA · contact PI
Mapping a clinically significant internalizing tumor epitope space$289,036
R01 · FY2013 · CA · contact PI
Internalizing human antibody-targeted nanosized siRNA therapeutics$324,824
R01 · FY2012 · CA · contact PI
Identifying antigens bound by novel scFvs targeting all subtypes of mesothelioma$310,970
R01 · FY2012 · CA · contact PI
Mapping a clinically significant internalizing tumor epitope space$307,484
R01 · FY2012 · CA · contact PI
Identifying antigens bound by novel scFvs targeting all subtypes of mesothelioma$310,970
R01 · FY2011 · CA · contact PI
Mapping a clinically significant internalizing tumor epitope space$307,484
R01 · FY2011 · CA · contact PI
Identifying antigens bound by novel scFvs targeting all subtypes of mesothelioma$320,588
R01 · FY2010 · CA · contact PI
Mapping a clinically significant internalizing tumor epitope space.$307,485
R01 · FY2010 · CA · contact PI
Internalizing antibody-targeted nanosized siRNA therapeutics$203,940
R21 · FY2010 · CA · contact PI
Selection of internalizing human antibodies targeting pancreatic tumor cells in s$169,950
R21 · FY2010 · CA · contact PI
Mapping a clinically significant internalizing tumor epitope space.$389,886
R01 · FY2009 · CA · contact PI
Selection of internalizing human antibodies targeting pancreatic tumor cells in s$203,940
R21 · FY2009 · CA · contact PI
Internalizing antibody-targeted nanosized siRNA therapeutics$169,950
R21 · FY2009 · CA · contact PI
Mapping a clinically significant internalizing tumor epitope space.$348,376
R01 · FY2008 · CA · contact PI
Mapping a clinically significant internalizing tumor epitope space.$265,136
R01 · FY2007 · CA · contact PI
Mapping a clinically significant internalizing tumor epitope space.$271,279
R01 · FY2006 · CA · contact PI
Tumor specific cell sruface epitope- molecular evolution$151,500
R21 · FY2005 · DK
Tumor specific cell surface epitope: molecular evolution$151,500
R21 · FY2004 · DK